ReviewJournal of translational medicine2007
Potency analysis of cellular therapies: the emerging role of molecular assays.
Review in Journal of translational medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.Journal of cellular and molecular medicine · 2024Article
- Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.Immuno-oncology technology · 2023Review
- Release Assays and Potency Assays for CAR T-Cell Interventions.Advances in experimental medicine and biology · 2023Article
- Potency Assay Development: A Keystone for Clinical Use.Advances in experimental medicine and biology · 2023Article
- A Comparative Analysis of the Wound Healing-Related Heterogeneity of Adipose-Derived Stem Cells Donors.Pharmaceutics · 2022Article
- Potency assays for human adipose-derived stem cells as a medicinal product toward wound healing.Stem cell research & therapy · 2022Review
- Article
- Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs).The AAPS journal · 2019Article
- Metabolomics and Cell Therapy in Diabetes Mellitus.International journal of molecular and cellular medicine · 2019Review
- Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.British journal of pharmacology · 2018Article
- CAR-T Cell Therapies From the Transfusion Medicine Perspective.Transfusion medicine reviews · 2016Review
- Rapid assay of stem cell functionality and potency using electric cell-substrate impedance sensing.Stem cell research & therapy · 2015Article
- Establishing a bone marrow stromal cell transplant program at the National Institutes of Health Clinical Center.Tissue engineering. Part B, Reviews · 2014Review
- Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection.Stem cells translational medicine · 2013Article
- Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.Journal of translational medicine · 2009Article
- A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Journal of translational medicine · 2008Article
- Differentiating human multipotent mesenchymal stromal cells regulate microRNAs: prediction of microRNA regulation by PDGF during osteogenesis.Experimental hematology · 2008Article
- Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells.Transfusion · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biological activity that is linked to a relevant biological property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such are flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of noncoding microRNA which play an important role in cellular development, differentiation, metabolism and signal transduction can distinguish different types of stem cells and leukocytes. Both gene and microRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and microRNA expression microarrays in potency testing of cellular therapies is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.